NCT06138990 (RAPID-01) is a Phase 2 clinical trial of Pharmacoscopy in AML, Adult, sponsored by ETH Zurich.

Who is sponsoring NCT06138990?

NCT06138990 is sponsored by ETH Zurich.

What drugs are being tested in NCT06138990?

Interventions in NCT06138990: Pharmacoscopy, Clinical standard-of-care (physician's choice).

What condition does NCT06138990 study?

NCT06138990 studies AML, Adult.

Is NCT06138990 still recruiting?

NCT06138990 is currently recruiting now. Last updated 16 May 2025.

Last reviewed 2025-05-16 · How we verify

NCT06138990: RAPID-01

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmacoscopy-guided Clinical Standard-of-care in r/r AML

Recruiting now Phase 2 Last updated 16 May 2025

What this trial tests

Phase 2 trial testing Pharmacoscopy in AML, Adult in 88 participants. Currently enrolling.

Timeline

2 September 2024

Primary endpoint
30 June 2026

30 June 2026

Quick facts

Lead sponsor	ETH Zurich
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	88
Start date	2 September 2024
Primary completion	30 June 2026
Estimated completion	30 June 2026
Sites	2 locations across Switzerland

Drugs / interventions tested

Pharmacoscopy
Clinical standard-of-care (physician's choice) — full drug profile →

Conditions studied

AML, Adult — all drugs for AML, Adult →

Sponsor

ETH Zurich — full company profile →

Who can join

Adults 18 to 70, any sex, with AML, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

With an overall survival of below 12 months, the outcome of relapsed/refractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage. The RAPID-01 trial aims to show for the first time in a randomized and controlled clinical trial that Pharmacoscopy (PCY), a functional precision medicine platform, helps improve clinical standard-of-care treatment selection for patients suffering from relapsed/refractory AML.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Functional precision medicine: the future of cancer care.
Acanda de la Rocha AM, Berlow NE, Azzam DJ. · · 2025 · cited 5× · PMID 39567286 · DOI 10.1016/j.molmed.2024.10.015
The functional imperative in high-grade glioma.
Goh LSH, Thng DKH, Ang YLE, Ho D, et al · · 2026 · PMID 41501375 · DOI 10.1038/s12276-025-01614-x
Neural Vulnerabilities in Glioblastoma: Rethinking Therapy Through Neuroactive Drug Repurposing.
Colobon PO, Lee S. · · 2025 · PMID 41218814 · DOI 10.14791/btrt.2025.0024

Verify or expand the search:

Other recruiting trials for AML, Adult

Currently open trials in the same condition.

NCT07328191 — Quality of Life-Guided Transfusion in Refractory MDS or AML · NA · recruiting
NCT07132684 — Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients · Phase 3 · recruiting
NCT06533761 — Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML · Phase 1 · recruiting
NCT07117422 — Venetoclax-Decitabine in Untreated Elderly/Unfit AML · NA · recruiting
NCT06313437 — Revumenib in Combination With 7+3 + Midostaurin in AML · Phase 1 · recruiting

Other ETH Zurich trials

Trials by the same sponsor.

NCT07435766 — Iron Absorption From IFA and MMS Supplements in Kenyan Women During the Second Trimester of Pregnancy · NA · recruiting
NCT07315295 — Maximizing the Benefits of Iron in Ready-to-Use Therapeutic Foods for Malnourished Children in Kenya · NA · recruiting
NCT07119411 — ICU Background Early Awareness for Critical deterioratiON · not yet recruiting
NCT06856291 — Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance · recruiting
NCT06814327 — Assessment of Organ Failure Risk Predictions in ICU · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06138990 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ETH Zurich
Last refreshed: 16 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06138990.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing